OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC 50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD).
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Cannabinoid Receptor | Products > Signaling Pathways > PPAR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.